Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A collaboration between the Russell group (Chemistry and Pharmacology) and the Davies group (Physiology, Anatomy and Genetics) has identified, via a chemical proteomics and phenotypic profiling strategy, the arylhydrocarbon receptor (AhR) as the molecular target of ezutromid, the utrophin modulator that recently completed a Phase 2 clinical trial in Duchenne muscular dystrophy patients.

Research results have been published in Angewandte Chemie.

Ezutromid (formerly SMT C1100) was identified through phenotypic screening approach, and developed as a first-in-class utrophin modulator for the treatment of the severe muscle wasting disease Duchenne muscular dystrophy (DMD). The clinical trial showed promising efficacy and evidence of target engagement after 24 weeks of treatment, but these effects were not seen after the full 48 weeks of the trial. Without knowledge of the mechanism of action of ezutromid, it was difficult to rationalise the lack of sustained clinical efficacy, and development of ezutromid was discontinued.

In this work, we demonstrate through a series of target identification and validation studies that ezutromid binds to AhR with high affinity, and antagonism of AhR by ezutromid leads to utrophin upregulation, thereby confirming AhR as a viable target for utrophin functional replacement therapies. This work paves the way for the first target-based disease modifying drug discovery program in DMD.

See https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201912392

Similar stories

New high-resolution imaging provides clue to SARS-CoV-2 leap to humans

A new paper, published this week in the journal Science, highlights cutting-edge imaging techniques used by the group of Professor Ben Davis to investigate the binding of SARS-CoV-2 to human cells.

Dr Mehmood Khan joins Pharmacology as a Visiting Fellow

We are delighted to announce the appointment of Dr Mehmood Khan as a Visiting Fellow in the Department

Fran Platt awarded 2023 Thudichum Medal

Pharmacology Head of Department, Professor Fran Platt, has been announced as the winner of the 2023 Thudichum Medal, presented by the Biochemical Society.

Join Pharmacology as the next Blaschko Fellow

Two year fellowship, offered in association with Linacre College, which offers full salary support, funding for travel and consumables and college accommodation. Join one of the existing groups in Pharmacology and develop your own research programme.